Celsion Corporation to Hold Third Quarter 2012 Financial

Celsion Corporation to Hold Third Quarter 2012 Financial Results
Conference Call on Monday, November 12, 2012 
LAWRENCEVILLE, NJ -- (Marketwire) -- 11/02/12 --  Celsion Corporation
(NASDAQ: CLSN), a leading oncology drug development company, today
announced that it would hold a conference call to discuss third
quarter 2012 results at 11:00 a.m. ET on Monday, November 12, 2012.
To participate in the call, interested parties may dial
1-888-364-3108 (Toll-Free/North America) or 1-719-457-2628
(International/Toll) and ask for the Celsion Corporation Third
Quarter 2012 Earnings Conference Call approximately ten minutes
before the call is scheduled to begin. The call will also be
broadcast live on the internet at http://www.celsion.com.  
The call will be archived for replay on Monday, November 12, 2012 at
2:00 p.m. ET and will remain available until Monday, November 19,
2012. The replay can be accessed at 1-877-870-5176 (Toll-Free/North
America) or 1-858-384-5517 (International/Toll) using Conference ID:
8948347. An audio replay of the call will also be available on the
Company's website, http://www.celsion.com, for 30 days after 2:00
p.m. ET on Monday, November 12, 2012.  
About Celsion Corporation 
Celsion is a leading oncology company dedicated to the development
and commercialization of innovative cancer drugs including
tumor-targeting treatments using focused heat energy in combination
with heat-activated liposomal drug technology. Celsion has research,
license, or commercialization agreements with leading institutions
including the National Institutes of Health, Duke University Medical
Center, University of Hong Kong, the University of Pisa, the UCLA
Department of Medicine, the Kyungpook National University Hospital
and the Beijing Cancer Hospital. 
For more information on Celsion, visit our website:
http://www.celsion.com. 
Celsion wishes to inform readers that forward-looking statements in
this release are made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Readers are
cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in
the course of research and development activities and in clinical
trials; FDA and regulatory 
risks; the need to raise funds for planned
drug development; the Company's history of losses and its expectation
of continuing to incur such losses; possible acquisitions of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in the Company's periodic reports filed
with the Securities and Exchange Commission. 
Investor Contact
David Pitts
Argot Partners
212-600-1902
David@argotpartners.com 
 
 
Press spacebar to pause and continue. Press esc to stop.